Encoded Therapeutics is shrinking its headcount by 29% as the gene therapy biotech draws resources away from its early-stage ...

Emil Kakkis; President, Chief Executive Officer, Director; Ultragenyx Pharmaceutical Inc Erik Harris; Executive Vice President, Chief Commercial Officer; Ultragenyx Pharmaceutical Inc Howard Horn; ...

Total Revenue of $560 million, exceeding guidanceCrysvita® revenue of $410 million and Dojolvi® revenue of $88 million2025 Financial ...

Reports Q4 revenue $164.88M, consensus $158.71M. “We have created a next-generation rare disease company on a pathway to profitability with ...

Rare diseases have become an attractive target for pharmaceutical companies both in Australia and internationally with ...

Encoded’s layoffs will mostly affect its technology and early-stage research and development functions. The move is expected ...

Dr. Eric Levine’s cutting-edge autism research at UConn School of Medicine is reprogramming the donated skin or blood cells ...

Ultragenyx's pipeline is rich with promising candidates, with setrusumab for osteogenesis imperfecta (OI) and GTX-102 for Angelman syndrome leading the charge. Setrusumab, currently in Phase 3 ...

The council approved the £20 per hour fees for non-residential care, which include social supports, day opportunities and ...

California Institute for Regenerative Medicine (CIRM) has awarded a $5.8 million translational research grant to a scientist at the University of California, Los Angeles (UCLA) to further support the ...